“三联”用药治疗骨质疏松性椎体压缩骨折术后残余痛的疗效观察

“TRIPLE” DRUG THERAPY IN POSTOPERATIVE RESIDUAL PAIN OF VERTEBRAL COMPRESSION FRACTURES

目的观察抗骨质疏松"三联"用药(钙尔奇D+骨化三醇胶丸+唑来膦酸)治疗骨质疏松性椎体压缩骨折经皮椎体成形术(percutaneous vertebral plasty,PVP)或经皮后凸椎体成形术(percutaneous vertebral plasty,PKP)术后残余痛的临床疗效。方法选择收治且符合纳入标准的患者51例,给予"三联"用药治疗。随访记录治疗前及治疗后1、3、6个月的疼痛视觉模拟评分、Oswestry功能障碍指数,以及治疗前及治疗后6个月骨密度测量结果,评价治疗效果;研究期间密切观察药物的不良反应以评估治疗的安全性。结果 51例患者治疗后疼痛明显缓解,骨密度显著改善,生活质量进一步提高;治疗期间有6例患者出现药物不良反应,4例可耐受,2例因过度敏感给予对症处理。结论抗骨质疏松"三联"用药治疗骨质疏松性椎体压缩骨折PVP或PKP术后残余痛安全有效,而且能有效改善骨密度,提高生活质量。

Objective To observe the clinical effect of anti-osteoporosis ＂triple＂ drug therapy （Caltrate D ＋ Calcitriol capsule ＋ Zoledronic acid） in treatment of the residual pain of vertebral compression fractures after percutaneous vertebral plasty（PVP） or percutaneous vertebral plasty （PKP）.Methods The study enrolled 51 patients in the standard,who were treated with Caltrate D ＋ Calcitriol capsule ＋ Zoledronic acid in the hospital.Visual analogue score （VAS） and Oswestry disability index were recorded before and 1,3,6 months after treatment and bone mineral density （BMD）was measured before and 6 months after treatment to evaluate the curative effect.Close observation was performed on drug adverse reactions to evaluate the safety of the treatment.Results Fifty-one patients had obvious pain relief after treatment and their BMD and quality of life were further improved.Six cases during study showed adverse drug reactions,4 cases could tolerate,2 cases were given symptomatic treatment because of over sensitivity.Conclusion Anti-osteoporosis ＂triple＂ drug therapy is safe and effective in treatment of the residual pain of vertebral compression fractures after percutaneous vertebral plasty or percutaneous vertebral plasty and the method can improve BMD and quality of life.